Fig. 3

miR-130a transgenic mice showed a decreased metastasis. a GEM strains crossbred to produce a myeloid-specific Tet-inducible miR-130a transgenic mouse. b Fold change of miR-130a in Gr-1⁺CD11b⁺ myeloid cells from miR-130a transgenic mice treated with doxycycline (DOX), which was quantified and normalized to that of untreated mice. c miR-130a expression in CD3⁺ T cells, CD19⁺ B cells, and Gr-1⁺CD11b⁺ myeloid cells from the splenocytes of the miR-130a transgenic mice treated with DOX (n = 3). d Left panel: qRT-PCR of TβRII in Gr-1⁺CD11b⁺ myeloid cells from the spleen of E0771 tumor-bearing miR-130a transgenic mice with DOX treatment (n = 3); right panel: Western blot of TβRII. e Number of E0771 metastatic nodules in miR-130a transgenic mice treated with DOX compared with control mice (Left panel: spontaneous metastasis, n = 12; Right panel: experimental metastasis, n = 7–9). f Metastasis nodule counts of Lewis lung carcinoma in miR-130a transgenic mice treated with DOX compared with control mice after tail vein injection. Lung nodules were counted after 14 days (n = 9). Representative lungs stained by Indian ink on the right panels. The data was represented as mean±SEM, and Student’s t test was performed. *p < 0.05, **p < 0.01, ***p < 0.001